About this Research Topic
The intersection of cardiomyopathy and heart failure are critical concerns in oncology due to the cardiotoxic effects of various cancer treatments and the impact of cancer-related factors on heart health. With advancements in cancer therapies, patients are living longer, making the management of cardiotoxicity increasingly important. Understanding how cancer therapies contribute to cardiovascular dysfunction and developing strategies to mitigate these effects is essential for comprehensive patient care. Recent research highlights the need for targeted interventions to manage these complications effectively.
The goal is to identify novel therapeutic approaches and management strategies to address cardiomyopathy and heart failure in oncology patients, ultimately improving patient care and outcomes. With this said, we welcome contributions that focus on the intersection of cardiomyopathy and heart failure in oncology, addressing the following themes:
• Cardiotoxicity of cancer therapies: Mechanisms and effects of cancer treatments on cardiac function.
• Prevention and management strategies: Approaches to mitigate cardiovascular complications in cancer patients.
• Impact of cancer-related factors: How cancer progression and systemic factors contribute to heart failure and cardiomyopathy.
• Novel therapeutic approaches: Innovative treatments and management strategies tailored for oncology patients with cardiovascular issues.
Disclaimer: Topic Editor Prabhu Mathiyalagan is the co-founder and CEO of Benthos Prime Central. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The goal is to identify novel therapeutic approaches and management strategies to address cardiomyopathy and heart failure in oncology patients, ultimately improving patient care and outcomes. With this said, we welcome contributions that focus on the intersection of cardiomyopathy and heart failure in oncology, addressing the following themes:
• Cardiotoxicity of cancer therapies: Mechanisms and effects of cancer treatments on cardiac function.
• Prevention and management strategies: Approaches to mitigate cardiovascular complications in cancer patients.
• Impact of cancer-related factors: How cancer progression and systemic factors contribute to heart failure and cardiomyopathy.
• Novel therapeutic approaches: Innovative treatments and management strategies tailored for oncology patients with cardiovascular issues.
Disclaimer: Topic Editor Prabhu Mathiyalagan is the co-founder and CEO of Benthos Prime Central. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Cardiomyopathy, heart failure, cancer therapy, cardiotoxicity, cardiovascular management
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
